CQDM

Vega Bioimaging specializes in enhancing cancer diagnostic accuracy. It offers a novel immunolabeling technology using colored nanobeads to target specific proteins in biopsy samples, providing precise and quantitative results. This enables better patient stratification and determination of eligibility for precision treatments. Vega's solution comprises a protein detection kit, a slide digitizing system, and AI-based quantification software, seamlessly integrating with existing microscopy systems.

NeuroTracker is a leading neurotech platform focused on enhancing cognitive performance through its scientifically validated training system. Backed by over 40 peer-reviewed studies and two decades of research in neuroscience, NeuroTracker specializes in multiple-object tracking to improve mental capabilities such as attention, executive function, and situational awareness. The platform is widely utilized by clinicians and therapists in neurovision and rehabilitation, as well as by elite athletes, military personnel, pilots, and gamers seeking to boost their cognitive abilities. By employing specialized technology and larger displays, NeuroTracker enables users to develop greater concentration, improved response times, and enhanced mental performance, ultimately transforming lives regardless of their starting point.

Oragenics, Inc. is a biotechnology company focused on developing novel antibiotics and treatments for infectious diseases, including coronaviruses and multidrug-resistant organisms. The company is advancing several product candidates, including OG716, an antibiotic in nonclinical testing for healthcare-associated infections, and AG013, which is in Phase II clinical trials for treating oral mucositis in cancer patients. Additionally, Oragenics is exploring LPT3-04, a naturally occurring compound aimed at weight loss, and SMaRT Replacement Therapy, a topical solution designed to protect against dental caries. The company has established collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV, for the development of AG013, as well as a license agreement with LPThera LLC for LPT3-04. Oragenics also has a partnership with Avid Bioservices, Inc. for the development of a coronavirus vaccine. Founded in 1996 and headquartered in Tampa, Florida, Oragenics remains committed to addressing significant health challenges through its innovative research and development efforts.

Giiant Pharma is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel diseases (IBD). Utilizing its proprietary Precision Delivery technology platform, Giiant designs gut-restricted, tissue-specific small molecule drug therapeutics that target specific biological pathways in gastroenterology. The company's lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug, which aims to improve drug tolerability while enhancing therapeutic effects. By releasing its active form specifically in the colon, Giiant's approach allows for targeted treatment at the site of inflammation, potentially preventing the worsening of patients' conditions.

Nomic is a bioengineering company focused on making the human proteome as accessible as the human genome. The company is developing the nELISA, a next-generation platform for measuring proteins at high throughput and scale. Nomic provides scientists with protein profiling solutions, allowing them to determine the scope and scale of their experiments. Their platform features cost-effective measurement of protein data and integrates smoothly with industry-standard cytometers for high-throughput analysis. Additionally, Nomic's technology enables the development of custom protein panels, leveraging nanotechnology to use DNA as a versatile linker to address issues of cross-reactivity in protein measurement.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, specializing in the development of therapeutics that target bone-related diseases. The company utilizes a unique prodrug platform that delivers bi-specific small-molecule therapeutics selectively to bone tissue, minimizing side effects associated with systemic exposure. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic, designed to potentially reverse bone loss linked to conditions such as Duchenne muscular dystrophy and osteoporosis. Mesentech's proprietary technology overcomes the challenges of delivering medications to the difficult-to-treat bone environment, which often requires high drug doses and can lead to significant side effects. Through pre-clinical in-vivo models, the effectiveness of this bone-targeting system has been confirmed, positioning Mesentech to address various low-bone-density disorders and enhance bone healing outcomes. The company was incorporated in 2013 and continues to innovate in the field of bone therapeutics.

ImStar Therapeutics Inc. is a biotechnology company based in Vancouver, Canada, established in 2012. The company specializes in developing treatments for amyotrophic lateral sclerosis (ALS), with a focus on addressing neurodegeneration. Its product pipeline includes IMS-088, a small-molecule compound targeting the immune system activation pathways involved in neurodegeneration, as well as TDP-43 Associated NF-kB Activation Inhibitors. ImStar Therapeutics aims to provide innovative therapies that can improve outcomes for patients suffering from ALS and potentially other neurodegenerative diseases.

Encycle Therapeutics is a biotechnology company based in Toronto, Canada, focused on developing drug-like macrocycles and membrane-permeable nacellins through its innovative platform technology. This approach allows for the rapid synthesis of nacellins, which have the potential to effectively target intracellular protein-protein interactions that are difficult to address with traditional small molecules and biologics. Encycle's nacellins can serve as cost-effective, oral alternatives to existing biologics, such as monoclonal antibodies. The company collaborates with various pharmaceutical firms to create a screening library of nacellins, many of which exhibit desirable drug-like properties. Encycle is actively developing nacellins aimed at treating integrin alpha-4-beta-7 related inflammatory bowel disease and SMURF2 associated fibrosis, with a focus on producing orally bioavailable inhibitors that promise improved safety and reduced immunogenicity compared to current biologic therapies targeting the same protein.

KalGene Pharmaceuticals Inc. is a privately held company based in Candiac, Canada, that specializes in the development of precision medicine for Alzheimer’s disease. Founded in 2006, KalGene collaborates with prominent clinician-scientists and academic institutions across North America and Europe. The company's focus is on creating targeted therapeutics and companion diagnostics aimed at enhancing clinical outcomes and survival rates through personalized medicine. By utilizing individual biological signatures, KalGene's approach seeks to predict patient responses to specific therapies, enabling healthcare providers to tailor treatments to meet the unique needs of each patient.

InDanio Bioscience Inc. is a privately-held drug discovery company based in Toronto, Canada, focusing on the development of new chemical entities that target nuclear receptor protein families. Established in 2008, the company employs a proprietary Ligand Trap system featuring 48 transgenic zebrafish lines, each expressing a different human nuclear receptor. This innovative approach allows for the simultaneous assessment of various drug properties, including delivery, stability, specificity, tissue selectivity, and toxicity. By utilizing selective and high-value target lines, InDanio aims to identify and characterize new hormonal regulators, as well as develop tissue-selective drugs, co-factors, and mechanisms of action for each nuclear receptor.